Business Wire | Aug 27, 2021 06:00AM EDT

Axonics(r) to Participate in Upcoming Investor Conferences

Aug. 27, 2021

IRVINE, Calif.--(BUSINESS WIRE)--Aug. 27, 2021--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management will present at the following virtual investor conferences:

Event: Wells Fargo Healthcare Conference Date: Thursday, September 9, 2021 Time: 12:00 p.m. Eastern Time

Event: Morgan Stanley Healthcare Conference Date: Monday, September 13, 2021 Time: 12:30 p.m. Eastern Time

Event: Baird Healthcare Conference Date: Wednesday, September 15, 2021 Time: 1:25 p.m. Eastern Time

Interested parties may access a live and archived webcast of each fireside chat by visiting the Axonics investor relations website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for patients with bladder and bowel dysfunction. The company's rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics' best-in-class urethral bulking agent, Bulkamid(r), provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210827005029/en/

CONTACT: Axonics contact: Neil Bhalodkar Investor Relations 949-336-5293 ir@axonics.com